Pure Bioscience Inc (PURE) Earnings Report, Financial Results, Financial analysis

Pure Bioscience Inc increased second quarter of 2023 net loss per share of $-0.01 compare to net loss per share of $-0.01 recorded in the same quarter a year ago a decrease compare to $-0.01 realized in previous quarter.

*second quarter of 2023*
Earnings Per Share	Revenues
$ -0.01	$ 0 Mill
Unch.	Unch. -4.57 %

Pure Bioscience Inc 's Revenue fell by -4.57 % in second quarter of 2023 (Jan 31 2023) year on year, to $0 million and declined by -15.71 % sequentially.

Pure Bioscience Inc is Expected to report next financial results on June 13, 2023.

More on PURE's Income Statement

PURE's NET INCOME

Pure Bioscience Inc 's in thesecond quarter of 2023 recorded net loss of $-1.060 million, an increase from net loss of $-0.702 million in II. Quarter a year ago.

Sequentially net loss advanced

More on PURE's Growth

Pure Bioscience Inc Inventories
Inventories declined by -33.11 % to $0.20 million from II. Quarter a year ago, sequentially inventories fell by -16.32 %. PURE's Cash flow In thesecond quarter of 2023 company's net cash flow was $1 million

Earnings quality

Pure Bioscience Inc does not pay out common stock dividend.

In trailing twelve-month period Pure Bioscience Inc payed $ -0.02 cash per share, on a free-cash flow basis .

Book value fell by -31.10 % sequentially to $0.02 per share, -19.31% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.02 per share from $ 0.03.

Company repurchased 0.00 million shares or 0.00 % in Jan 31 2023.

• More on PURE's Dividends

Market Capitalization (Millions)	13
Shares Outstanding (Millions)	111
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	2
Net Income (TTM) (Millions $)	-4
Cash Flow (TTM) (Millions $)	1
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Pure Bioscience Inc does not pay out common stock dividend.

In trailing twelve-month period Pure Bioscience Inc had negative $ -0.02 cash flow per share, on a free-cash flow basis .

Book value fell by -31.10 % sequentially to $0.02 per share, -19.31% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.02 per share from $ 0.03.

Company repurchased 0.00 million shares or 0.00 % in Jan 31 2023.

• More on PURE's Balance Sheets

Market Capitalization (Millions)	13
Shares Outstanding (Millions)	111
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	2
Net Income (TTM) (Millions $)	-4
Cash Flow (TTM) (Millions $)	1
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Pure Bioscience Inc

PURE's Financial Statements and Analysis